Oxford BioDynamics launches its Checkpoint Inhibitor response test in the US
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
Subscribe To Our Newsletter & Stay Updated